Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Remestemcel-L by Mesoblast for Graft Versus Host Disease (GVHD): Likelihood of Approval
Remestemcel-L is under clinical development by Mesoblast and currently in Pre-Registration for Graft Versus Host Disease (GVHD). According to GlobalData,...